---
title: "AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297172017.md"
description: "AstraZeneca (AZN) and Amgen (AMGN) shares dropped in pre-market trading despite positive late-stage trial results for Tezspire, a new esophagus drug developed in collaboration. The drug met its primary goals for treating a chronic inflammatory disorder. This negative market reaction contrasts with the potential boost expected from the success, especially following recent pipeline setbacks for AZN in cancer and heart disease treatments."
datetime: "2026-08-27T10:46:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297172017.md)
  - [en](https://longbridge.com/en/news/297172017.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297172017.md)
generator: "portal-rs"
---

# AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success

Shares in pharmaceuticals giant AstraZeneca (AZN) and peer Amgen (AMGN) both dropped in pre-market trading despite hailing successful trial results for a new esophagus drug. AZN said that its asthma drug Tezspire, developed in collaboration with Amgen, had met ‌the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the esophagus. This should have been a boost to AZN stock after a series of drug pipeline setbacks this year for diseases such as cancer and heart problems. AZN's share price is down 3.63% in the year-to-date.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Robbins Farley Purchases New Shares in Astrazeneca Plc $AZN](https://longbridge.com/en/news/297893929.md)
- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [UK regulator suspends Amgen's Tavneos for new patients over unreliable data](https://longbridge.com/en/news/297642592.md)
- [AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories](https://longbridge.com/en/news/297649754.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**